WestPark Capital Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $48

WestPark Capital has initiated coverage on Aligos Therapeutics (NASDAQ: ALGS) with a Buy rating. The firm has set a price target of $48 for the company's stock.